This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more by reading our privacy policy. Read more
Selected current partnerships
Selected R&D partnerships
| Partner* | Project | Type** | Year estab. |
|---|---|---|---|
| Bristol-Myers Squibb (Medarex) (US) | Human Antibodies | Research and Commercialisation Agreement | 2000 |
| Bristol-Myers Squibb (ZymoGenetics Inc.) (US) | IL-21 embodiments | License Agreement | 2009 |
| Bristol-Myers Squibb (ZymoGenetics Inc.) (US) | Factor XIII | Development & License Agreement | 2004 |
| Bristol-Myers Squibb (ZymoGenetics Inc.) (US) | IL-20 embodiments | License Agreement | 2001 |
| Cellartis AB and Lund University (SE) | Beta Cell therapy | Research Collaboration & License | 2008 |
| Combine (SE) | Inflammation | Research Agreement | 2009 |
| Emisphere (US) | Oral GLP-1 | Development and License Agreement | 2008 |
| Emisphere (US) | Insulin | Development and License Agreement | 2010 |
| G2 Inflammation Pty. Ltd. (AU) | C5a Receptor | Research Collaboration & License | 2005 |
| Innate Pharma S.A. (FR) | NK-cell targets | Joint Research, Development, option and License Agreement | 2006 |
| Innate Pharma S.A. (FR) | Inflammation | Research, Development & License | 2003 |
| Merrion (IE) | Oral GLP-1 | Research Agreement | 2009 |
| Merrion (IE) | Oral Insulin | Research Agreement | 2008 |
| Pacira Pharmaceuticals Inc. | Sustained release technology | Development and License Agreement | 2011 |
| St Vincent's Hospital Sydney (AU) | Macrophage Inhibitory Cytokine | Research and License agreements | 2009 |
| VLST (US) | Virulence factors Target identification and validation | Research and License Agreement | 2008 |
Selected R&D partnerships - outlicensed
| Partner* | Project | Type** | Year estab. |
|---|---|---|---|
| Amicus Therapeutics Inc. (US) | Plicera (isofagomine tartrate) | License Agreement | 2005 |
| Argos Therapeutics (US) | Antibodies for treatment of autoimmune diseases | Development & License Agreement | 2006/2010 |
| Bristol-Myers Squibb (ZymoGenetics Inc.) (US) | IL-21 Protein | License and Transfer Agreement | 2009 |
| Helsinn Healthcare S.A. (CH) | GH releasing peptides and small molecules | License Agreement | 2007 |
| Innate Pharma S.A. (FR) | Anti-KIR | Research, Development & License Agreement | 2008 |
| TransTech Pharma Inc. (US) | Glucokinase Activator for treatment of diabetes | License Agreement | 2007 |
Selected product partnerships
| Partner* | Project | Type** | Year estab. |
|---|---|---|---|
| Ben Venue Laboratories (US) | Glucagen® (Glucagon) | Distribution | 1999 |
| Boehringer Ingelheim GmbH (DE) | NovoNorm®, Prandin® (Repaglinide) | Development & License Agreement | 1990 |
| Cephalon Inc. (US) | Gabitril® (Tiagabine) | License Out (Worldwide excl. JP, Latin America, MX, CA) | 2000 |
| Dainippon Sumitomo Pharma Co.,Ltd. (JP) | Surepost® (Repaglinide) | Development & License Agreement | 2004 |
| Eisai Pharmaceuticals (JP) | Glucagen® (Glucagon) | Distribution | 1999 |
| Menarini Industrie Farmaceutiche (IT) | NovoNorm® (Repaglinide) | Co-Marketing (ES) | 2002 |
| Mochida Pharmaceuticals (JP) | Novo-Heparin® (heparin sodium), Novo-Protamin Sulfate® (protamin sulphate) | Distribution | 2003 |
*Country abbreviation after company name signifies nationality of partner
** Country abbreviation after agreement type signifies which geographical area the agreement covers, no country abbreviation indicates a multiregional or global agreement.
